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Abstract
Objective: To test the hypothesis that measles vaccination was involved in the 
pathogenesis of ASD as evidenced by signs of a persistent measles infection or 
abnormally persistent immune response shown by circulating measles virus  or 
raised antibody titres in MMR vaccinated children with ASD compared with controls  .
Design: Case-control study community based 
Methods: A community sample of vaccinated children aged 10-12 years in the UK 
with ASD (N=98) and two control groups of similar age, one with special 
educational needs but no ASD (N=52) and one typically developing group 
(N=90), were tested for measles virus and antibody response to measles in 
serum.
Results: No difference was found between cases and controls for measles antibody 
response. There was no dose response relationship between autism symptoms 
and antibody levels. Measles virus nucleic acid was amplified by RT-PCR in 
PMBC from one case with autism and two typically developing children. There 
was no evidence of a differential response to measles virus or the measles 
component of the MMR in children with ASD, with or without regression, and 
controls who had either one or two doses of MMR. Only one child from the 
control group had clinical symptoms of a possible enterocolitis.  
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Introduction
Recent studies of the prevalence of autism spectrum disorders (ASD) have 
found rates between 6 and 12 per thousand, significantly higher than previous 
estimates, depending on the strictness with which the diagnostic criteria are 
applied1,2,3. Although widening of diagnostic concept, improved ascertainment and 
other methodological aspects of more recent studies are likely to be major causes of 
the increased rate, and despite the fact that autism is known to have a strong genetic 
basis; concerns about environmental risk factors for an increased prevalence have 
inevitably been raised.  
In 1998, a report of a small case series of 12 children and no control group 
suggested that measles, mumps and rubella (MMR) vaccination might be linked to 
the development of autism spectrum disorders 4.  A subsequent larger case series 
described a condition referred to as ‘autism enterocolitis’, which was postulated to be 
associated with MMR vaccination and specifically with regression in autism 5. 
Several epidemiological studies found no association between MMR 
vaccination and autism spectrum disorder 6,7,8. , however, fear about MMR 
vaccination resulted in reduction of uptake of combined MMR vaccine, which fell from 
92% in 1995-96 to 80% by 20049, risking exposure of the population to a measles 
epidemic and outbreaks in susceptible groups 10. There continues to be an impact on 
parents of children with autism 11 and general public concern of risk which is reflected 
in parental decisions about MMR vaccination 12,13 
.… Elevated levels of measles antibodies have been reported in 
autism14. .Two laboratories have reported the detection of measles virus, one by 
conventional reverse transcriptase polymerase chain reaction (RT-PCR) in 3 cases 
of autism15 and another by real-time Taqman PCR16, the latter in intestinal samples of 
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75/91 patients with ASD compared to 5/70 control patients.  The origin and 
characterisation of the fragments of measles virus genome described in these 
studies has not been established and concerns about the scientific methods 
employed widely expressed. Two recent studies have failed to find measles virus 
genome by real-time PCR in children with ASD compared with controls in peripheral 
blood mononuclear cells (PBMC) rather than gut mucosal samples. 17,18  
We took advantage of a new geographically defined study of the prevalence of 
ASD (Special Needs and Autism Project; SNAP)1, to test the hypothesis that measles 
vaccine was involved in the pathogenesis of ASD as evidenced by signs of a 
persistent measles infection or abnormally persistent immune response shown by 
circulating measles virus  or raised antibody titres in MMR vaccinated children with 
ASD compared with controls  in particular in children with ASD and a history of 
regression. Measles virus replicates in a range of cells during infection including the 
upper respiratory tract, intestinal cells, several T cell lineages and macrophages. 
Replication occurs for similar periods in these different sites. An earlier study had 
suggested virus detectable in peripheral blood mononuclear cells (PBMC) PCR in 
blood samples in children with ASD 15 . We used PBMC in this study as proxy for gut 
mucosal cells which were not obtained for ethical reasons. 
Methods
Participants. The population studied is a cohort of 56,946 children born 
between July 1st 1990 and December 31st 1991 from 12 districts in the South Thames 
region of the UK. At age 9-10 years children with a statement of special educational 
needs (SEN) (1733; 218 of whom had a local ASD diagnosis) or a local diagnosis of 
ASD but no SEN statement (37) were screened using the Social Communication 
Questionnaire (SCQ)19.  Stratification by local diagnosis and high, medium and low 
SCQ score was used to derive a subset (255) who received an in-depth diagnostic 
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assessment (see figure 1 for a flow chart of the process and Baird et al for further 
explanation). The diagnostic assessment included standardized clinical observation 
(Autism Diagnostic Observation Schedule – Generic (ADOS-G))20 and parent 
interview assessments of autism symptoms (Autism Diagnostic Interview-Revised 
(ADI-R))21, language and IQ, psychiatric comorbidity and a medical examination (see 
Table 1). Children were classified using ICD-10 research criteria as childhood autism, 
other ASD or no ASD by clinical consensus using all sources of information. The 
ASD group was divided into a ‘broad ASD’ and ‘narrow autism’ group, the latter 
defined as meeting autism criteria on the ADI-R, the ADOS-G and clinical consensus 
of ICD-10 childhood autism and the broad ASD defined as all other cases meeting 
clinical consensus  of any ASD. The total number of ICD-10 autism symptoms was 
recorded. Those who experienced ‘regression’ were divided into a ‘definite language 
regression group’ defined as the loss of 5 or more words used communicatively 
during a 3 month period  and a ‘lower level regression’ group who had not achieved 
the 5 word stage at the time of regression but had reported regression of words or 
skills in social communicative or play behaviour. The ‘no ASD’ group had a variety of 
diagnoses, learning difficulties, specific language or literacy impairments, ADHD, 
cerebral palsy, deafness and visual impairment. 
After obtaining consent, of the 255 children seen for an in-depth assessment, 
sufficient blood suitable for analysis was collected from 101 cases with an ASD 
diagnosis (mean age = 11.6 years, SD .88), and 54 SEN controls with a non-ASD 
diagnosis (mean age = 12.7 years, SD .88). The age span reflects the time scale of 
the diagnostic project. 
A further 98 typically developing (TD) controls, born at the same time, 
attending two mainstream schools within the same geographic area who did not have 
a statement of special educational needs and who consented to venepuncture were 
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recruited.  The SCQ was used to screen out possible cases of autism and eight 
cases were subsequently excluded from analysis on the basis of scores of at least 
15, the cut-off recommended for identifying likely cases of ASD19. The mean age of 
the 92 TD controls was 12.2 years (SD .33). 
Gastrointestinal symptoms (GIS) reflecting the presentation of GI symptom 
constellations in general clinical paediatric practice were assessed using a 22 item 
questionnaire completed by the main caregiver (in preparation)  Current (in the last 
three months) and past symptoms were elicited. A ‘possible enterocolitis’ group was 
constructed from the presence of 2 or more of the following 5 current gastro intestinal 
symptoms : current persistent diarrhoea (defined as loose/watery stools three or 
more times a day >14 days), current persistent vomiting (occurring at least once per 
day or more than five  times in a  week), current weight loss, current persistent 
abdominal pain (3 or more episodes severe enough to interfere with activity); current 
blood in stool; plus past  diarrhoea >14 days duration and excluding current 
constipation.
Vaccination.(see figure 1) Information about MMR vaccination was obtained 
about all children using district records, parent records, and GPs.  235 children had 
received the first MMR vaccination, 98 (97% of the group) with ASD, 52 (96%) SEN 
controls, and 85 (94%) TD controls. 106 children received the stage 2 MMR 
vaccination (first introduced in 1996) (35 (36%) children with ASD, 18 (35%) SEN 
controls and 53 (62%) TD controls). Five children who lacked evidence of at least 
one MMR vaccination were excluded from the analysis.  
Studies show 95% seroconversion for measles after the first MMR vaccination 
with the second dose of MMR converting most of those who did not with the first 
vaccination and inducing only a transient rise in antibody proportional to the earlier 
response in earlier responders22. Thus it is justifiable to include every child who had 
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had at least one MMR vaccination in a case-control comparison of vaccinated 
children: 98 ASD cases (32 narrow autism; 66 broad ASD); 52 SEN controls and 90 
mainstream (TD) controls. However, for completeness, children who had had only 
one MMR and those who had had two MMR vaccinations were analysed separately 
and then were combined .  For some analyses, the SEN non-ASD controls and TD 
controls are compared separately and then in combination to form a total control 
group of 142. The 98 ASD cases are analysed as broad ASD and narrow autism 
separately and in combination.
Laboratory Tests. Clotted and anti-coagulated blood samples (in 
ethylenediaminetetraacetic acid) were couriered to the laboratory on the day of 
collection for processing. Serum was separated and stored at -20°C until tested for 
antibody. Samples were processed using the amplicor kit and then stored at -70 °C 
until tested for measles virus. Samples were batched and the laboratory was blind to 
case control status.
Genome Detection. Detection of measles virus in the EDTA sample was 
conducted on peripheral mononuclear cells after concentration using the amplicor 
whole blood preparation kit (Roche). Satisfactory EDTA samples for this were 
available from 94/98 ASD cases and 130/142 SEN and TD controls.  Samples were 
tested for presence of measles genome after extraction of RNA using the Magnapure 
extractor.  Three RT-PCR assays were used; published assays for M gene23 and N 
gene RT-PCRs were used 24.  A RT-PCR for H gene using AB1 PRISM 7000 
sequence detector platform (TaqMan) was developed 25.  Assays were run for 40 
cycles and data analysed according to the manufacturer’s instructions.  For the real-
time assay, the following primers and probes were used:
Gene Primer Position Sequence (5’-3’) Product
H gene Forward 117-140 GGCTGTTCTGTTTGTCATGTTTGT 68
7
Reverse 161-184 GATGAAGTCTAATGCCTGCAATGG
Probe 141-156 CAACCCGATCAAGCTC
The sensitivity of the assay was determined to be 2 genome copies. Samples were 
tested to ensure they were adequate using a β2 microglobulin housekeeping gene 
PCR with a sensitivity of 10 genome copies per reaction mixture. 
Antibody Studies. Serum samples were tested for measles IgG antibody by 
plaque reduction neutralisation test (PRN). PRN was chosen because recent 
evaluation has demonstrated its greater sensitivity over commercially available EIA 
tests26. Measles antibody was quantified in international units to control variation 
using the international reference standard sera for PRN27.  
Statistics. All summary statistics and analyses of antibody response are based 
on log10 transformed milliInternational Units per milliLitre (mIU/mL) and undertaken in 
Stata 9 28.  Having tested for homogeneity of variance (Bartlett test), we report 
ANOVA F and Scheffé tests for the 4-group comparison of Typically Developing 
(TD), SEN-No ASD, Broad ASD and Autism. In addition, in view of the variety of 
specific alternative hypotheses proposed, we report both further pairwise 
comparisons of combined groups, a group defined by regressive autism and a linear 
trend test over the quintiles of the ICD-10 autism symptom score. Results are also 
reported for these additional analyses using Wilcoxon rank based tests29 that enable 
the inclusion of subjects with no detectable antibody response (coded as 0).  P-
values from these rank based tests are denoted p*. All p-values and confidence 
intervals for these additional paired comparisons are nominal with no correction for 
multiple testing. 
   
Results
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Descriptive statistics of TD, SEN, broad ASD and narrow autism groups are 
shown in Table 1. 
Measles Virus Assays. Samples from all cases contained detectable β2 
microglobulin gene by PCR.  All samples were negative in measles H gene RT-PCR 
assay.  56 samples (based on availability of sufficient nucleic acid) were also tested 
and negative in the N gene RT-PCR. One sample from a case and 2 samples from 
controls were reactive in the M gene PCR.  These PCR products were sequenced; a 
genotype C2 measles strain was characterised in one case (who had narrow autism 
but no regression history) and a measles vaccine strain and a D6 strain from 2 
typically developing mainstream controls.  These sequences were unlike any 
previous isolates seen in the laboratory.  The results were not repeatable; the 3 
reactive samples were negative when retested in the M gene PCR. 
Antibody Response to Measles. Eight subjects (1 typically developing, 5 SEN 
Non ASD, 1 broad ASD and 1 narrow autism) who had received MMR vaccination 
had no detectable measles IgG antibody by PRN suggesting that the attenuated 
measles virus did not replicate and triggered no immunological response. There was 
no difference in mean log10 (mIU/mL) measles titre between those with one or two 
MMR vaccinations (difference = 0.00, CI(-.12,.11), p=.94, p*=.62). 
Figure 2 shows the similarity of distributions of measles PRN responses by group, 
combined by MMR number.  The plots give no indication of extreme titres in the ASD 
and autism groups that fall outside of the distribution among the controls. The overall 
difference of means test indicated no significant differences (F(3,223) p=.13) with the 
most significant of the 6 Scheffé paired comparisons giving p=.23.  The 
corresponding tests for those with a single MMR were F(3,126) p=.20 with most 
significant Scheffé p=.20, and for those with two MMR were F(3,93) p=.66 with most 
significant Scheffé p=.74.
9
       The combined control group mean log10-titre was not significantly lower than the 
narrow autism group (difference 0.05 CI( -0.08,0.18), (F(1,194) p=0.45, p*=0.26), nor 
the ASD group (difference 0.08 CI(-0.07,0.25), F(1,160), p=0.29, p*=0.26) nor the 
combined autism/ASD group (difference 0.06, (-0.05,0.17), F(1,225), p=0.27, 
p*=0.26).  This comparison of the combined case and control groups had 80% power 
to detect a mean titre difference of 45% (or 0.16 log10(mIU/mL).  Within the autism 
groups there was no trend of PRN response over ICD-10 symptom quintiles (p=0.99; 
p*=0.63).
Regression was reported in 23 children with ASD but PRN titres were not 
significantly higher among these than combined controls (difference –0.12 CI (-
0.30,0.06), F(1,162) p=0.18, p*=0.33).
’Possible ‘enterocolitis’ as defined above, was found in only I child who did not 
have ASD or regression.. He had current and past diarrhoea and abdominal pain and 
was in the combined control group.  No child had a previous diagnosis of 
inflammatory bowel disorder. 
Discussion
No difference was detected in the measles antibody distribution or in measles 
virus in ASD cases and controls whether the children had received the first, second 
or both MMR vaccinations.  This remained true when the analysis was restricted to 
ASD cases with a history of regression. Only one child had symptoms of a possible 
enterocolitis and this was in the control group. 
 This is one of three virological case control studies which have failed to 
demonstrate any association between measles vaccination and ASD using well 
validated techniques17,18. In the D’Souza study18, children were 26-30 months from 
vaccination contrasting with approximately 9 years in this study with identical 
conclusions. The report from D’Souza et al. also describes an exhaustive validation 
10
of the molecular detection methods used in the only study to detect measles genome 
in ASD cases16 demonstrating that the methods used can generate false positive 
results.
The strengths of this study are that the cases with ASD were from a well 
characterised community, not clinic, derived sample. The sample is the largest 
reported.. Regression was clearly defined. The diagnostic process allowed a ‘dose 
response’ of ICD10 symptoms to antibody titre to be analysed. All children had well 
documented vaccination history.  A highly sensitive methodology was used for 
measles antibody assay. The laboratory techniques employed to collect, extract, 
store and test samples for measles genome used well-established, block-based RT-
PCR assays, which have been shown to be highly sensitive in an international 
comparative study24.  Laboratory analysis was conducted blind to case control status. 
A real-time RT-PCR was also used 25. This platform was used in earlier studies and 
although of comparable sensitivity to nested conventional PCR, risk of contamination 
is reduced. PBMC’s were used to look for measles by RT-PCR because they are a 
site of viral replication in acute measles infection and they have been reported to 
contain measles genome by RT-PCR in a small number of autism children15. 
There are two possible explanations for the finding of one RT-PCR reactive 
samples in 98 cases of ASD and 2 in the 90 TD children. Immunity to measles is not 
always complete30 and measles genome has been detected in the PBMC’s of 
asymptomatic individuals during measles epidemics31. C2 and D6 measles 
genotypes have been detected in the UK population before 2002.  The finding could 
also be due to laboratory cross contamination, which can be problematic with RT-
PCR assays.
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Limitations of the study: 
The TD group were not randomly selected from the total population for 
reasons of time, convenience and cost. Parents were informed the study was about 
MMR vaccination and it is possible that a biased group responded to the request to 
participate.  Satisfactory blood samples were not obtained in 100 children, both ASD 
cases and SEN controls, for a variety of reasons, including refusal by the young 
person concerned, haemolysation in transport etc. We did not obtain gut mucosal 
samples for ethical reasons; PBMC were used for measles genome assay justified as 
a site of known viral replication and appropriate proxy for gut mucosal cells. Gut 
symptoms were elicited but the children were too old for accurate reporting of 
retrospective gut symptoms confidently contemporaneous with MMR vaccination. A 
clinically relevant definition of enterocolitis based on persistent symptoms has 
therefore been used for this paper. 
It is of public health relevance that there is a differential uptake of MMR2 
across the groups with both ASD and SEN control groups having lower uptake and 
hence less exposure to measles virus. This may reflect parental concern about 
vaccination following a diagnosis of developmental abnormality. Only 29% (20/70) of 
children who had a local diagnosis of ASD received MMR2 compared with 50% 
(14/28) who had no local ASD diagnosis. 
What is already known on this topic
• Public concern about a putative link between MMR vaccination and ASD has 
resulted in lower uptake of MMR vaccine
• Epidemiological studies have shown no link between MMR and ASD
What this study adds
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• There is no difference between ASD cases and controls in circulating measles 
genome or measles antibody levels
• There is no evidence of an altered persisting immunological response following 
either one or two MMR vaccinations in ASD cases with and without a history of 
regression 
• There is no evidence of increased enterocolitis in the ASD group with regression.
• In this cohort, children were less likely to receive MMR2 following diagnosis of a 
developmental problem.
Funding
The study was funded by the Department of Health, the Wellcome Trust, the National 
Alliance for Autism Research (NAAR) and Remedi.
Role of Funding Source. The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation or writing of the report. The 
corresponding author had full access to all the data in the study and final 
responsibility for the decision to submit for publication. 
Conflicts of interest
MA and DB have given unpaid advice to lawyers in MMR and MR litigation.
GB has acted as an occasional expert witness for the diagnosis of autism. AP 
receives royalties from SCQ and ADOS-G instruments. PBS has acted as an expert 
witness in the matter of MMR/MR vaccine litigation. All other authors have no 
conflicts of interest.
Ethical Approval
South Thames MREC 00/1/50
Kent & Medway LREC WK153/8/02
Role of authors
13
GB, ES, TC and DB obtained funding, DB, MA, BT and LJ were responsible for the 
laboratory tests.  TL, SC, and DM collected data and samples. PS  was responsible 
for gastrointestinal assessment. AP had overall responsible for the statistical 
analysis. All authors contributed to the paper.
Acknowledgments
We would like to thank the parents and children who participated, Dr Sameena 
Shakoor and Ms Beryl Packman as well as other colleagues for help with data and 
sample collection.
The Corresponding Author has the right to grant on behalf of all authors and does 
grant on behalf of all authors an exclusive licence (or non exclusive for government 
employees) on a world wide basis to the BMJ publishing group Ltd and its licensees 
to permit this article (if accepted) to be published in Archives of Disease  in 
Childhood editions and any other  BMJPGL products to exploit all subsidiary rights as 
set out in the licence ( http://adc.bmjjournals.com/ifora/licence.dtl)
14
References
1 Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D et al. Prevalence 
of disorders of the autism spectrum in a population cohort of children in South 
Thames: the Special Needs and Autism Project (SNAP). Lancet 2006;368:210-5
2 Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool 
children: Confirmation of high prevalence. Am J Psychiatry 2005;162:1133-41
3 Green H, McGinnity A, Meltzer H, Ford T, Goodman R. Mental Health of children 
and Young People in Great Britain, 2004. London: Stationary Office, 2005.
4 Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-
lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental 
disorder in children. Lancet 1998;351:637-41. Retraction in: Murch SH, Anthony A, 
Casson DH, Malik M, Berelowitz M, Dhillon AP, et al. Lancet 2004;363:750
5 Wakefield AJ, Anthony A, Murch SH, Thomson M, Montgomery SM, Davies S, et 
al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 
2000;95:2285-95
6 Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A 
population-based study of measles, mumps, and rubella vaccination and autism. N 
Engl J Med 2002; 347:1477-82
7 Smeeth L, Cook C, Fombonne E, Heavey L, Rodrigues LC, Smith PG, et al. MMR 
vaccination and pervasive developmental disorders: a case-control study. Lancet 
2004;364:963-9
8 Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. 
Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a 
causal association. Lancet 1999;353:2026-9
15
9 Health Protection Agency. Annual COVER report 2004/2005. Available from: 
http://www.hpa.org.uk/infections/topics_az/vaccination/AnnCOVER2005A.pdf
10 Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it by 
2010? BMJ 2006;333:890-5
11  Hilton S, Hunt K, Petticrew M  MMR Marginalised, misrepresented and rejected?
Autism: a focus group study. Arch Dis Child 2007;92:322-7
12 Hadjikoumi I, Niekerk KV, Scott C. MMR Catch up Campaign: reasons for refusal 
to consent. Arch Dis Child 2006;91:621
13. Smith A Yarwood J Salisbury D Tracking mother’s attitudes to MMR 
immunisation 1996-2006. Vaccine publ. online March 2007 
http://dx.doi.org/10.1016/j.vaccine.2007.02.071
14 Singh VK, Jensen RL. Elevated levels of measles antibodies in children with 
autism. Pediatr Neurol 2003;28:292-4
15 Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. 
Detection and sequencing of measles virus from peripheral mononuclear cells from 
patients with inflammatory bowel disease and autism. Dig Dis Sci 2000;45:723-9
16 Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, et al. Potential 
viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 
2002;55:84-90
17 Afzal M.A, Ozoemena L.C, O'Hare A, Kidger K.A, Bentley M.L, and Minor, P.D. 
Absence of detectable measles virus genome sequence in blood of autism children 
who have had their MMR vaccination during the routine childhood immunization 
schedule of U.K.  J Med Virol 2006;78:623-30
18 D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in 
peripheral blood mononuclear cells from children with autism spectrum disorder.
Pediatrics 2006;118:1664-75
16
19 Rutter M, Bailey A, Lord C. Social Communication Questionnaire. Los Angeles, 
LA : Western Psychological Services; 2003
20 Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC et al. The 
Autism Diagnostic Observation Schedule-Generic: A standard measure of social and 
communication deficits associated with the spectrum of autism. J Autism Dev Disord 
2000;30:205-23
21 Lord C, Rutter M, Lecouteur A. Autism Diagnostic Interview-Revised - A revised 
version of a diagnostic interview for caregivers of individuals with possible pervasive 
developmental disorders. J Autism Dev Disord 1994;24:659-85
22 Dilraj A, Cutts FT, Bennett JV, Fernandez de Castro J, Cohen B, Coovadia HM. 
Persistence of measles antibody two years after revaccination by aerosol or 
subcutaneous routes. Pediatr Infect Dis J 2000;19:1211-3
23 Jin L, Richards A, Brown DWG. Development of a dual target-PCR for detection 
and characterization of measles virus in clinical specimens. Mol Cell Probes 
1996;10:191-200
24 Afzal MA, Osterhaus AD, Cosby SL, Jin L, Beeler J, Takeuchi K, et al.  Comparative 
evaluation of measles virus-specific RT-PCR methods through an international 
collaborative study. J Med Virol 2003;70:171-6
25 Thomas B, Beard S, Jin Li, Brown KE*, Brown DWG. Development and evaluation 
of a real-time PCR assay for rapid identification and quantification of measles virus. J 
Med Virol  in press * Corresponding Author
26 Cohen BJ, Audet S, Andrews N, Beeler J on behalf of the WHO working group on 
measles plaque reduction neutralization test.  Plaque reduction neutralization test for 
measles antibodies. Geneva: WHO; Submitted.
27 Forsey T, Heath AB, Minor PD. The 1st international standard for anti-measles 
serum. Biologicals 1991;19:237-41
17
28 Stata Statistical Software Release 9.0: Survey Data Manual College Station, TX: 
Stata Corporation; 2005.
29 Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4:87-90 
30 Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud  SR, 
Orenstien WA. Measles antibody: re-evaluation of protective titers. J Infect Dis 
1990;162:1036-42
31 Sonoda S, Nakayama T. Detection of measles virus genome in lymphocytes from 
asymptomatic healthy children. J Med Virol 2001;65:381-7
18
Table 1 Sample Descriptive Statistics: Autism Symptoms and IQ (means (SD))
TD SEN
(No ASD)  
Broad ASD Narrow Autism
N 90 52 66 32
SCQ scorea 4.26
(3.59)
9.03
(7.54)
22.03
(6.88)
28.03
(5.06)
ADI-commb NA 5.37
(3.84)
14.73
(5.57)
18.09
(3.32)
ADI-socc NA 5.27
(4.85)
19.70
(6.66)
24.69
(3.53)
ADI-repd NA 1.23
(1.35)
6.00
(3.17)
7.59
(2.17)
ICD-10 syme NA 1.62
(1.25)
7.21
(2.18)
10.31
(1.64)
ADOS-commf NA 0.96
(1.10)
2.05
(1.35)
5.59
(2.09)
ADOS-socg NA 2.84
(2.33)
5.27
(3.10)
10.59
(1.93)
ADOS-reph NA 0.60
(0.77)
1.74
(1.64)
3.66
(2.12)
IQ NA 78.46
(20.21)
78.94
(22.49)
63.84
(17.67)
Age in
Years
12.2
(0.33)
12.7
(0.89)
11.6
(0.90)
11.7
(0.90)
a SCQ = Social Communication Questionnaire
b ADI-comm = Autism Diagnostic Interview-Revised Communication domain 
algorithm score (4-5 years)
c ADI-soc = Autism Diagnostic Interview-Revised Reciprocal Social Interaction 
domain algorithm score (4-5 years)
d ADI-rep = Autism Diagnostic Interview-Revised Repetitive and Stereotyped 
Behaviours domain algorithm score (4-5 years)
e ICD-10 sym = ICD-10 symptom count (0-12)
f ADOS-comm = Autism Diagnostic Observation Schedule - Generic Communication 
domain algorithm score
g ADOS-soc = Autism Diagnostic Observation Schedule - Generic Social domain 
algorithm score
h ADOS-rep = f ADOS-comm = Autism Diagnostic Observation Schedule - Generic 
Repetitive domain algorithm score
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Figure 2 Measles PRN responses for the typical/mainstream, SEN, (broad) ASD and 
narrow autism groups
log10 (mIU/mL in measles PRN)
Key to boxplot: The box indicates the interquartile range and thick black line the 
median of each distribution (Geometric means: Typ.Dev. 2.95; SEN No ASD 2.79; 
Broad ASD 2.94; Narrow Autism 2.98). Whiskers extend to the highest and lowest 
observed values or, if less extreme, 2.5 times the inter-quartile range from the 
median.
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Cohort screened with SCQb (N = 1770)
Local ASD diagnosis and SENc, N = 218
Local ASD diagnosis, but no SEN, N = 37
No local ASD diagnosis, but SEN, N = 1,515
Figure 1.  Sample selection
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in for further assessment
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response/ opted out of 
assessment
N = 735
No blood sample N=100
Declined blood test/ sample clotted/  
insufficient sample for testing
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Received MMR2
Local ASD diagnosisASDNo 
ASDReceived MMR22015No MMR25214
Received MMR1 N= 52
No MMR1 N = 2
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